Submit your email to push it up the queue
Chiesi USA, Inc., a subsidiary of the Chiesi Group, is a prominent player in the pharmaceutical industry, headquartered in the United States. Established in 1935, the company has made significant strides in developing innovative therapies, particularly in the fields of respiratory, neonatology, and rare diseases. With a strong presence across major operational regions in North America, Chiesi USA is dedicated to improving patient outcomes through its unique portfolio of products. The company is renowned for its commitment to sustainability and patient-centric solutions, offering a range of inhalation therapies and specialty pharmaceuticals that stand out for their efficacy and safety. Chiesi USA has garnered recognition for its contributions to healthcare, positioning itself as a leader in the biopharmaceutical sector, while continuously striving for excellence in research and development.
How does Chiesi USA, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Chiesi USA, Inc.'s score of 76 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Chiesi USA, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Chiesi Farmaceutici S.p.A., which provides emissions data and climate commitments at a higher corporate level. Chiesi Farmaceutici S.p.A. has set ambitious climate commitments, including science-based targets for emissions reductions. However, specific reduction targets or achievements for Chiesi USA, Inc. have not been detailed in the available information. The company is part of a broader initiative to enhance sustainability and reduce carbon footprints across its operations, inheriting commitments and performance metrics from its parent organisation. As a current subsidiary, Chiesi USA, Inc. aligns with the sustainability goals established by Chiesi Farmaceutici S.p.A., which include participation in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). These initiatives aim to drive significant reductions in greenhouse gas emissions across all scopes, although specific figures for Scope 1, 2, or 3 emissions for Chiesi USA, Inc. have not been disclosed. In summary, while Chiesi USA, Inc. does not present specific emissions data or reduction targets, it is committed to the overarching climate strategies of its parent company, Chiesi Farmaceutici S.p.A., focusing on sustainability and emissions reduction in the pharmaceutical industry.
Access structured emissions data, company-specific emission factors, and source documents
2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|
Scope 1 | 21,729,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 17,985,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 |
Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Chiesi USA, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.